340B Health always does a great job bringing together key healthcare stakeholder voices at the annual 340B summer conference. This event provides a terrific forum for education, discussion and insight into what's working well with the program and where there are opportunities for improvement. This year it seemed the overall industry discussion around the program had […]
May 10, 2015 - Curant Health Director of patient Services and ImpleDespite advances in technology, physicians spend less time with patients than ever before. On average, physician interaction with a patient lasts only eight minutes, which amounts to about 12% of his or her time on the job, according to a study published in The […]
May 26, 2015 - Curant Health President & CEO, Patrick Dunham, in Fierce Practice Management - When it comes to practice-management headaches, the hassle involved in obtaining prior authorizations from insurers often leads the list of complaints. And while many elements of fee-for-service reimbursement structures will begin to disappear as the industry moves toward value-based […]
June 22, 2015 - Curant Health COO, Marc O'Connor, in MedCity News - $1,000 per month for life cholesterol drugs brings immense pressure on prescribers to ensure outstanding medication adherence by patients. The pharmaceutical industry is about to wade into a new battlefield with payers and prescribers. A new class of drugs known as PCSK9 inhibitors restricts a […]
In his latest Managed Healthcare Executive article, Curant Health COO, Marc O’Connor, discusses how to reduce avoidable healthcare costs through the use of innovative medication management with enhanced MTM. There is one certainty in the healthcare industry: there will always be high costs. Fortunately, a large portion of current healthcare spending is avoidable, and all […]
June 22, 2015 - Curant Health COO, Marc O'Connor, in MedCity News - $1,000 per month for life cholesterol drugs brings immense pressure on prescribers to ensure outstanding medication adherence by patients. The pharmaceutical industry is about to wade into a new battlefield with payers and prescribers. A new class of drugs known as PCSK9 inhibitors […]
June 19, 2015 - Curant Health COO, Marc O'Connor, in Specialty Pharmacy Times - There is no question that one of the changes brought about by the ACA is increased scrutiny of healthcare insurance plans by consumers and employers alike. New regulations, economic pressures and patient expectations are changing healthcare in US overall plan quality. […]
It seems that I always leave the Armada Specialty Pharmacy Summit with a handful of takeaway items that stick with me for the remainder of the year. The 2015 conference was no exception. The big learnings I took away from this year’s event all seem to relate to healthcare misalignment and the seismic shift taking […]
May 27, 2015 - Curant Health COO, Marc O'Connor, in Specialty Pharmacy Times - Amidst the health care industry’s seismic shift away from fee-for-service to value-based care, the pharmaceutical industry remains firmly at odds. Manufacturers need to recoup massive R&D costs for curative therapies and PBMs need to drive down costs for their plan sponsors. […]
May 26, 2015 - Curant Health President and CEO, Patrick Dunham, in Fierce Practice Management - When it comes to practice-management headaches, the hassle involved in obtaining prior authorizations from insurers often leads the list of complaints. And while many elements of fee-for-service reimbursement structures will begin to disappear as the industry moves toward value-based […]
